Camber touts readiness for DSCSA compliance

Camber announced that it is fully prepared to meet the new Drug Supply Chain Security Act requirements, ensuring enhanced traceability, verification and safety across the pharmaceutical supply chain. 

With robust systems for verification routing services, exception handling, master data management and inventory control, Camber noted that it integrates advanced technology to maintain compliance and uphold the highest product safety standards.

[Read more: Camber - Number 1 in Generic Approvals]

• Status: 100% fully aggregated from bottle to pallet.
• Testing: Completed extensive testing with multiple customers, achieving a 95-100% success rate.
• VRS: Utilizing TraceLink for product authentication since November 2022.
• Handling: Currently conducting EPCIS data testing with all customers.
• GTIN Data: Global Trade Item Numbers are provided to all participating customers via HDAs.

[Read more: NACDS urges FDA, HHS to preserve medication access as supply chain pursues DSCSA compliance]

Camber added that it is fully prepared for DSCSA compliance by November 2024. “We are increasing our inventory to support our customers during the transition period if their other suppliers are not fully compliant,” the company said. 

Find more information from the FDA about DSCSA.